During a live event, Jeffrey V. Matous, MD, discussed flexible dosing and the need to expand use in community practices for ...

Multiple myeloma causes lytic or osteolytic lesions, which are areas of damage caused by cancerous plasma cells blocking normal bone growth. While painful, they can be managed. Multiple myeloma is ...

On-body delivery systems for subcutaneous isatuximab could enable patient self-administration, according to Xavier Leleu, MD, PhD, improving convenience and transforming treatment for ...

Researchers sought to determine whether CAR-T therapy could improve HR-QoL scores for patients with relapsed or refractory multiple myeloma.

I share how traveling fueled my passion for life, how myeloma changed my journeys, and how new mobility options have opened ...

Patients with relapsed/refractory myeloma from lower socioeconomic groups face worse quality of life, even in countries with universal health care, according to Francesco Sparano, MSc, of the ...

New CAR T-cell therapy shows remarkable efficacy in treating relapsed multiple myeloma, achieving high response rates and ...

If approved, daratumumab will be the first authorised treatment option for patients with smouldering multiple myeloma at high-risk of developing multiple myeloma, offering the potential for disease ...

In this exclusive MedPage Today video, investigator Shahzad Raza, MD, of the Cleveland Clinic Cancer Institute, explains why ...